Cipla Drugs
- All
- News
- Videos
-
Why Trump's 100% Pharma Tariffs May Not Impact Indian Drugmakers Much
US President Donald Trump has said his administration will impose 100 per cent import tariffs on branded or patented pharmaceutical drugs from October 1, unless the pharma companies have or are building their manufacturing units in America.
-
Cipla, Glenmark Recall Asthma Drugs Made In Indore From US Market
Drug makers Cipla and Glenmark are recalling products from the American market due to manufacturing issues, according to the US health regulator.
-
Five Indian Drugmakers To Jointly Start Trial Of Merck & Co's Covid Drug
Fivegeneric drugmakers, including Cipla and Dr Reddy's Laboratories, said on Tuesday they would jointly conduct a clinical trial of Merck & Co's anti-viral drug to treat mild COVID-19 in non-hospitalised patients in the country.
-
Moderna Approved For Emergency Use, 4th Vaccine Okayed By India
The government on Tuesday cleared the fourth vaccine for emergency use in the country, the US-made Moderna.
-
Delhi's LNJP Hospital Begins Free Antibody Cocktail Therapy For Covid Patients
The Monoclonal Antibody Cocktail used to treat mild to moderate "high risk" Covid patients is now available at Delhi's Lok Nayak Jai Prakash Narayan Hospital (LNJP) for free.
-
3 Indian Firms To Make, Sell US's Eli Lilly's Baricitinib Drug For Covid Treatment
Eli Lilly and Co said on Monday it had signed licensing agreements with three Indian generic drugmakers to expand the availability of its arthritis drug baricitinib in the country for treating COVID-19 patients.
-
Cipla To Make, Sell US's Eli Lilly's Baricitinib Drug For Covid Treatment
Indian drugmaker Cipla Ltd said on Monday it has entered into a licensing agreement with U.S. company Eli Lilly and Co to make and sell Lilly's arthritis drug baricitinib for the treatment of COVID-19 patients.
-
Merck Taps 5 Indian Drugmakers To Expand Covid Drug Production
Merck & Co Inc said on Tuesday it had partnered with five Indian generic drugmakers, including Cipla Ltd and Sun Pharmaceutical Industries Ltd, to expand production and access to its experimental COVID-19 drug.
-
Indian Demand For COVID-19 Drug Remdesivir Rising Sharply: Cipla
Demand for COVID-19 antiviral drug remdesivir is rising sharply in India, a top executive at drugmaker Cipla Ltd said on Monday, even as experts remain divided over its effectiveness.
-
India's Shortage Of Remdesivir Is Easing, Says Producer Cipla
India's supply of antiviral drug remdesivir and generic equivalents is stabilising after shortages of the vital COVID-19 medicine at hospitals, according to a top executive at one of the country's big drugmakers, Cipla Ltd.
-
Cipla Set To Launch Favipiravir Drug For Treatment Of COVID Patients
Pharmaceutical firm Cipla is all set to launch Favipiravir, developed by the Council of Scientific and Industrial Research (CSIR) in a cost-effective process, for the treatment of COVID-19 patients, according to an official statement on Thursday.
-
High Court To Resume Hearing On Petitions Against Centre's Ban On Drugs
Delhi High Court is likely to resume today the hearing on petitions by over 30 pharmaceutical majors, including Pfizer, Glenmark, Procter and Gamble (P&G) and Cipla, challenging the government's decision to ban sale of some of their fixed dose combination medicines.
-
Supreme Court's decision on Novartis AG to benefit poor patients, say pharma companies
Poor patients will have easier access to quality medicines with the Supreme Court rejecting Swiss firm Novartis' patent plea for its cancer drug Glivec, according to domestic manufacturers.
-
Supreme Court backs generics in Novartis drug patent ruling
India's Supreme Court rejected Monday a patent bid by Swiss drug giant Novartis in a landmark ruling that activists say will protect access to cheap generic drugs and save lives in developing nations.
-
Why Trump's 100% Pharma Tariffs May Not Impact Indian Drugmakers Much
US President Donald Trump has said his administration will impose 100 per cent import tariffs on branded or patented pharmaceutical drugs from October 1, unless the pharma companies have or are building their manufacturing units in America.
-
Cipla, Glenmark Recall Asthma Drugs Made In Indore From US Market
Drug makers Cipla and Glenmark are recalling products from the American market due to manufacturing issues, according to the US health regulator.
-
Five Indian Drugmakers To Jointly Start Trial Of Merck & Co's Covid Drug
Fivegeneric drugmakers, including Cipla and Dr Reddy's Laboratories, said on Tuesday they would jointly conduct a clinical trial of Merck & Co's anti-viral drug to treat mild COVID-19 in non-hospitalised patients in the country.
-
Moderna Approved For Emergency Use, 4th Vaccine Okayed By India
The government on Tuesday cleared the fourth vaccine for emergency use in the country, the US-made Moderna.
-
Delhi's LNJP Hospital Begins Free Antibody Cocktail Therapy For Covid Patients
The Monoclonal Antibody Cocktail used to treat mild to moderate "high risk" Covid patients is now available at Delhi's Lok Nayak Jai Prakash Narayan Hospital (LNJP) for free.
-
3 Indian Firms To Make, Sell US's Eli Lilly's Baricitinib Drug For Covid Treatment
Eli Lilly and Co said on Monday it had signed licensing agreements with three Indian generic drugmakers to expand the availability of its arthritis drug baricitinib in the country for treating COVID-19 patients.
-
Cipla To Make, Sell US's Eli Lilly's Baricitinib Drug For Covid Treatment
Indian drugmaker Cipla Ltd said on Monday it has entered into a licensing agreement with U.S. company Eli Lilly and Co to make and sell Lilly's arthritis drug baricitinib for the treatment of COVID-19 patients.
-
Merck Taps 5 Indian Drugmakers To Expand Covid Drug Production
Merck & Co Inc said on Tuesday it had partnered with five Indian generic drugmakers, including Cipla Ltd and Sun Pharmaceutical Industries Ltd, to expand production and access to its experimental COVID-19 drug.
-
Indian Demand For COVID-19 Drug Remdesivir Rising Sharply: Cipla
Demand for COVID-19 antiviral drug remdesivir is rising sharply in India, a top executive at drugmaker Cipla Ltd said on Monday, even as experts remain divided over its effectiveness.
-
India's Shortage Of Remdesivir Is Easing, Says Producer Cipla
India's supply of antiviral drug remdesivir and generic equivalents is stabilising after shortages of the vital COVID-19 medicine at hospitals, according to a top executive at one of the country's big drugmakers, Cipla Ltd.
-
Cipla Set To Launch Favipiravir Drug For Treatment Of COVID Patients
Pharmaceutical firm Cipla is all set to launch Favipiravir, developed by the Council of Scientific and Industrial Research (CSIR) in a cost-effective process, for the treatment of COVID-19 patients, according to an official statement on Thursday.
-
High Court To Resume Hearing On Petitions Against Centre's Ban On Drugs
Delhi High Court is likely to resume today the hearing on petitions by over 30 pharmaceutical majors, including Pfizer, Glenmark, Procter and Gamble (P&G) and Cipla, challenging the government's decision to ban sale of some of their fixed dose combination medicines.
-
Supreme Court's decision on Novartis AG to benefit poor patients, say pharma companies
Poor patients will have easier access to quality medicines with the Supreme Court rejecting Swiss firm Novartis' patent plea for its cancer drug Glivec, according to domestic manufacturers.
-
Supreme Court backs generics in Novartis drug patent ruling
India's Supreme Court rejected Monday a patent bid by Swiss drug giant Novartis in a landmark ruling that activists say will protect access to cheap generic drugs and save lives in developing nations.
